Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scholar Rock HoldingFRA:2QK +0.71%34 EV-to-EBITDA is -16.16 as of Aug. 21, 2026. GuruFocus rates FRA:2QK with a GF Score™ of 34/100. The stock has 5 warning signs investors should review. Among 406 Biotechnology companies, Scholar Rock Holding ranks worse than 246305.17% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Scholar Rock Holding's enterprise value is €5,511.07 Mil.
Scholar Rock Holding's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-340.95 Mil. Therefore, Scholar Rock Holding's EV-to-EBITDA for today is -16.16.
The historical rank and industry rank for Scholar Rock Holding's EV-to-EBITDA or its related term are showing as below:
FRA:2QK'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -32.47 Med: -6.16 Max: 0.63
Current: -16.23
During the past 10 years, the highest EV-to-EBITDA of Scholar Rock Holding was 0.63. The lowest was -32.47. And the median was -6.16.
FRA:2QK's EV-to-EBITDA is ranked worse than 100% of 406
companies
in the Biotechnology industry
Industry Median: 14.4
vs FRA:2QK: -16.23
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Scholar Rock Holding (FRA:2QK) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Scholar Rock Holding's PE Ratio (TTM) for today is calculated as:
Scholar Rock Holding's share price for today is €46.50.
Scholar Rock Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.966.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Scholar Rock Holding's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2QK vs DFTX, DNTH, ORKA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Scholar Rock Holding's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scholar Rock Holding EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scholar Rock Holding's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Scholar Rock Holding's EV-to-EBITDA falls into.
Scholar Rock Holding's current Enterprise Value is €5,511.07 Mil.
Scholar Rock Holding's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-340.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scholar Rock Holding (FRA:2QK) has a EV-to-EBITDA of -16.16 as of Aug. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Scholar Rock Holding. According to the industry distribution chart, Scholar Rock Holding ranks #999999 out of 406 companies in the Biotechnology industry.
Is Scholar Rock Holding's EV-to-EBITDA too high?
Scholar Rock Holding's current EV-to-EBITDA is -16.16. Based on the distribution chart, Scholar Rock Holding ranks #999999 out of 406 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Scholar Rock Holding has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Scholar Rock Holding's EV-to-EBITDA compare to DFTX and DNTH?
According to the Biotechnology industry distribution chart, Scholar Rock Holding ranks #999999 out of 406 companies for EV-to-EBITDA. This places Scholar Rock Holding in the lower half of its industry. The industry median EV-to-EBITDA is 14.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.40, based on 406 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Scholar Rock Holding. For the Biotechnology industry, the median EV-to-EBITDA is 14.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scholar Rock Holding's current EV-to-EBITDA is -16.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scholar Rock Holding stock overvalued right now?
Scholar Rock Holding (FRA:2QK) has a current EV-to-EBITDA of -16.16. The current EV-to-EBITDA is -16.16. Scholar Rock Holding's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Scholar Rock Holding (FRA:2QK), the current EV-to-EBITDA is -16.16 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
34GF Score
Get the complete analysis for FRA:2QK
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2QK has been successfully added to your 
